Drug rimonabant

Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in ...

Taranabant is the generic name given to a new trial medication being tested for the fight against obesity. With obesity being such a huge problem in society today, there is a large demand for medications fighting it. And currently there is a new medication in the works which ...

There are two types of diabetes. Type 1 occurs when the body doesn't produce any insulin. People with type 2 diabetes either don't produce enough insulin or their cells ignore the insulin. Nearly 95% of people with diabetes have type 2. Diabetes medicines are not as effective as diet and physical ...

A new animal study on rimonabant (Acomplia / Zimulti) has identified yet one more possible health benefit for this controversial diet drug: it appears to reduce obesity-related liver damage that can lead to cirhossis of the liver. A team of researchers led by Mohammed Bensaid of Sanofi-Aventis, the company ...

It looks like that FDA is not in rush at all. Rimonabant acomplia has been approved for sale in Mexico since Nov. 9th. after couple of EU states /like UK/ this drug finally arrived to America. This diet pil ...

Acomplia is the brand name of the medication while Rimonabant is the name of its active ingredient. Acomplia (Rimonabant), after its launch in the June 2006, has conquered a vast portion of weight loss drug market. This success of Rimonabant is the result of the benefits which it has given ...

Top Marketeer to Promote Taranabant, Competitor to Acomplia Merck's development of taranabant, a diet drug which has been ...

Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. "Acomplia is a selective CB1 endocannabinoid receptor antagonist." It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It ...

Accomplia Rimonabant diet treatment blocks circuitry in brain that gives body cravingsAcomplia Rimonabant ( accomplia ), is a new treatment which helps ...

rimonabant(rimonabant cost) is the product launched by Sanofi-Aventis of France. This high efficacy appetite suppressant was launched in the UK anti-obesity drug market in the month of June. The drug is a ray of hope for million suffering from obesity. rimonabant cost has a chemical named Rimonabant which blocks the ...